HMGB1 and acute kidney injury: Agents such as glycyrrhizin, quercetin not only provide evidence for the efficacy of HMGB1-targeted therapies but also offer insights into the broader application of anti-inflammatory strategies in CI-AKI management (Oh et al., 2021; Luo et al., 2022).